A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma
This is a randomized, double-blind, multicenter, Phase 3 study to compare the efficacy and safety of LY01015 and Opdivo®（Nivolumab Injection）combined respectively with fluorouracil plus cisplatin in participants with unresectable advanced, recurrent or metastatic previously untreated esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
DRUG: LY01015|DRUG: Fluorouracil|DRUG: Cisplatin|DRUG: Opdivo®
Objective Response Rate(ORR) as assessed by IRC, from baseline to week 16
Objective Response Rate(ORR) as assessed by IRC and investigator, from baseline to week 24|Disease Control Rate (DCR), up to 2 years|Duration of Response (DOR), up to 2 years|Progression-Free Survival (PFS), up to 2 years|16-week Progression-Free Survival Rate, from baseline to week 16|24-week Progression-Free Survival Rate, from baseline to week 16|Overall Survival (OS), up to 2 years|Incidence and severity of adverse effects (AEs), up to 2 years|Incidence of Anti-Drug Antibodies (ADA) and Neutralizing Antibodies (Nab), up to 2 years
This is a randomized, double-blind, multicenter, Phase 3 study to compare the efficacy and safety of LY01015 and Opdivo®（Nivolumab Injection）combined respectively with fluorouracil plus cisplatin in participants with unresectable advanced, recurrent or metastatic previously untreated esophageal squamous cell carcinoma.